AMG 162
Sponsors
Amgen
Conditions
Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple MyelomaLow Bone Mineral DensityPostmenopausal OsteoporosisProstate Cancer
Phase 3
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
CompletedNCT00089674
Start: 2004-08-01End: 2010-05-11Updated: 2018-10-17
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
CompletedNCT00091793
Start: 2004-08-31End: 2009-03-31Updated: 2010-12-31
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
CompletedNCT00325468
Start: 2006-05-01End: 2012-08-02Updated: 2017-08-01
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
CompletedNCT00950911
Start: 2009-07-31End: 2012-04-30Updated: 2014-02-11